Viridian Therapeutics ( (VRDN) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Viridian Therapeutics shares slid as investors weighed the long wait before key regulatory decisions and clinical readouts that could move the business forward. The market appears cautious ahead of several make-or-break milestones rather than reacting to any single negative event.
The company said its veligrotug BLA is under U.S. priority review, with an FDA decision expected by June 30, 2026, and a potential mid-2026 launch for thyroid eye disease. Viridian also filed for European approval and expects important REVEAL-1 and REVEAL-2 trial results soon, while analysts remain broadly positive on the stock’s outlook.
More about Viridian Therapeutics
YTD Price Performance: -7.01%
Average Trading Volume: 1,443,878
Technical Sentiment Signal: Buy
Current Market Cap: $2.81B
For further insights into VRDN stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.